This completely updated 2nd edition to Kalorama’s popular 2003 study focuses on the market applications of current and advanced drug delivery technology to the development of new and modified pharmaceutical products in the United States. Taking a strategic view of the various therapeutic areas on which drug delivery is anticipated to have its greatest impact, the report considers the options that the current technologies present, the progress that is being made in these fields, and the reception these new products are likely to experience in the marketplace.
In particular, the 400-page study examines the market potential of modified-delivery therapeutics in the following therapeutic categories:
- Cardiovascular Diseases (including Coronary Stents),
- Cancer,
- Central Nervous System (CNS) Applications,
- Diabetes,
- Fertility Control and Women’s Health,
- Infectious Diseases, and
- Pulmonary Diseases (including upper respiratory conditions)
This report discusses the economic aspects of certain advanced drug delivery technologies and applications, and their impacts on formularies, insurers and patients. In addition to the market analysis and a thorough review of available technologies and those in development, the report extensively profiles the leading delivery technology companies, noting their portfolios, development pipelines, financial performance, and strategic partnerships.
Market analysis for this report considers the markets modified drug delivery products only in the United States. The focus of the report is on the application of advanced drug delivery technology in the improvements of existing pharmaceuticals and the facilitation of the delivery and commercialization of new therapeutics emerging from the biotechnology and biopharmaceutical industries.
The analysis presented in this report is based on data from a combination of company, government, industrial, institutional and private sources. It includes information from extensive literature reviews, as well as interviews and discussions with experts in the field, including experts in drug delivery technology, as well as medicinal chemists, research scientists, and business development and marketing managers engaged in the field.
- Executive Summary
- BACKGROUND
- SCOPE AND METHODOLOGY
- TECHNOLOGY AND MARKET OPPORTUNITIES
- Polymers and Biomaterials
- Oral Drug Delivery Devices
- Pulmonary Drug Delivery
- Drug Eluting Stent Technology
- Percutaneous Drug Delivery Technology
- Ophthalmic Drug Delivery
- Colloidal Drug Delivery Technologies
- Site/Organ Specific Drug Delivery
- Needle-Free Drug Delivery Technology
- SIZE AND GROWTH OF MARKET
- Table Estimated U.S. Market Potential for Delivery-Modified Therapeutics 2004–2014
- Table Estimated United States Market Potential for Delivery-Modified Therapeutics by Application Area (Cardiovascular, Cancer, CNS, Diabetes, Women's Health, Infectious Disease, Pulmonary) 2004–2014
- Drug Delivery Technologies
- Table Key Companies Active in Drug Delivery Technology and Products
- PHARMACODYNAMICS AND DRUG DELIVERY
- Small Organic Molecules
- Pharmaceutical Proteins
- Vaccines
- Genes and Antisense Drugs
- POLYMERS AND BIOMATERIALS
- Table Commonly Used Polymeric Materials for Controlled Drug Release Systems
- Non-Absorbable Polymers
- Polyamine Analogs
- Magnapore Polymers
- Natural Biopolymers
- Intelligent Polymers
- ORAL DRUG DELIVERY DEVICES
- Extended-Release Technology
- Delayed-Release Technology
- Immediate-Dissolution Technology
- PULMONARY DRUG DELIVERY
- Table Key Companies Active in Pulmonary Drug Delivery Technology by Application Area/Type of Participation (Diabetes, Pain, Nicotine, OEM Provider, Co-Developer, Asthma, COPD, Cystic Fibrosis, Endocrinology, Reproductive/Hormones, Sleep Disorders, Growth Hormone Deficiency, Prostate Cancer)
- Drug Eluting Stent Technology
- Table Pharmaceutical Candidates for Drug-Eluting Stents
- Table Companies Active in Drug-Eluting Stent Commercialization by Segment of Participation (Drugs, Coatings, Stents, Drug-Eluting Stents)
- PERCUTANEOUS DRUG DELIVERY TECHNOLOGY
- Intranasal Delivery
- Iontophoresis
- Phonophoresis
- Table Phonophoresis/Cortisol Trial Results
- Electroporation
- OPHTHALMIC DRUG DELIVERY
- COLLOIDAL DRUG DELIVERY TECHNOLOGIES
- SITE/ORGAN SPECIFIC DRUG DELIVERY
- IMPLANTABLE DRUG DELIVERY SYSTEMS
- NEEDLE-FREE DRUG DELIVERY TECHNOLOGY
- MICRONEEDLE TECHNOLOGY
- NANOBIOTECHNOLOGY
- Drug Delivery Applications and Markets
- BACKGROUND
- Table Estimated U.S. Market Potential for Delivery Modified Therapeutics by Therapeutic Area (Cardiovascular, Cancer, CNS, Diabetes, Women's Health, Infectious Disease, Pulmonary) 2004–2014
- CARDIOVASCULAR DISEASES
- Technology Applications
- Table Currently Marketed Drug Delivery Modified Cardiovascular Products (Brand, Generic, Manufacturer, Application)
- Table Pharmaceutical Candidates for Drug-Eluting Stents
- Table Companies Active in Drug-Eluting Stent Commercialization by Segment of Participation (Drugs, Coatings, Stents, Drug-Eluting Stents)
- Market Assessment
- Table Potential U.S. Market for Drug Delivery–Modified Cardiovascular Drugs and Drug-Eluting Stents 2004–2014
- Technology Applications
- CANCER
- Technology Applications
- Table Currently Marketed Drug Delivery Modified Cancer Therapy Products
- Market Assessment
- Table Potential U.S. Market for Drug Delivery–Modified Cancer Therapeutics by Type (Cytotoxic, Hormone, Blood Restorative, Pain Management, Infection Control) 2004–2014
- Technology Applications
- CENTRAL NERVOUS SYSTEM (CNS) APPLICATIONS
- Technology Applications
- Table Currently Marketed Drug Delivery Modified CNS Therapy Products
- Market Assessment
- Table Potential United States Market for Drug Delivery–Modified CNS Therapeutics: 2004–2014
- Technology Applications
- Table Currently Marketed Drug Delivery–Modified Diabetes Therapeutics
- Market Assessment
- Table Potential U.S. Market for Drug Delivery–Modified Diabetes Therapeutics by Type (Insulin, Oral Hypoglycemics) 2004–2014 Manufacturers' Revenues (in billions)
- Technology Applications
- FERTILITY CONTROL AND WOMEN'S HEALTH
- Technology Applications
- Table Currently Marketed Drug Delivery–Modified Fertility and Women's Health Products
- Technology Applications
- MARKET ASSESSMENT
- Table Potential United States Market for Drug Delivery–Modified Fertility Control and Women's Health Drugs: 2004–2014
- INFECTIOUS DISEASES
- Technology Applications
- MARKET ASSESSMENT
- Table Currently Marketed Drug Delivery–Modified Infectious Disease Drugs
- Table Potential United States Market for Drug Delivery–Modified Infectious Disease Therapeutics 2004–2014
- PULMONARY DISEASES
- Technology Applications
- Table Currently Marketed Drug Delivery–Modified Pulmonary Disease Therapeutics
- Market Assessment
- Table Potential United States Market for Drug Delivery–Modified Pulmonary Disease Therapeutics 2004 – 2014
- Technology Applications
- BACKGROUND
- Company Profiles
- OVERVIEW
- ABBOTT VASCULAR DEVICES DIVISION OF ABBOTT LABORATORIES
- ALKERMES,INC.
- ANDRX CORPORATION
- BIOJECT MEDICAL TECHNOLOGIES
- BIOVAIL CORPORATION
- BOSTON SCIENTIFIC
- CIMA LABS INC., A CEPHALON COMPANY
- CORDIS CORPORATION AJOHNSON &JOHNSON COMPANY
- CYDEX,INC.
- DELSITE BIOTECHNOLOGIES
- DURECT CORPORATION
- ELAN CORPORATION PLC
- ENZON PHARMACEUTICALS,INC.
- GENZYME GENERAL
- GUIDANT CORPORATION AJOHNSON &JOHNSON COMPANY
- GUILFORD PHARMACEUTICALS INC.
- MEDTRONIC,INC.
- NASTECH PHARMACEUTICAL COMPANY INC.
- NEKTAR THERAPEUTICS,INC.
- SKYEPHARMA PLC
- Conclusions and Strategic Implications
- FIRST CONCLUSION
- Implications:
- SECOND CONCLUSION
- Implications:
- THIRD CONCLUSION
- Implications:
- FOURTH CONCLUSION
- Implications:
- FIFTH CONCLUSION
- Implications:
- SIXTH CONCLUSION
- Implications:
- SEVENTH CONCLUSION
- Implications:
- FIRST CONCLUSION
- Glossary
- List of Companies
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook